| First Author | Oury J | Year | 2021 |
| Journal | Nature | Volume | 595 |
| Issue | 7867 | Pages | 404-408 |
| PubMed ID | 34163073 | Mgi Jnum | J:324232 |
| Mgi Id | MGI:7264828 | Doi | 10.1038/s41586-021-03672-3 |
| Citation | Oury J, et al. (2021) Mechanism of disease and therapeutic rescue of Dok7 congenital myasthenia. Nature 595(7867):404-408 |
| abstractText | Congenital myasthenia (CM) is a devastating neuromuscular disease, and mutations in DOK7, an adaptor protein that is crucial for forming and maintaining neuromuscular synapses, are a major cause of CM(1,2). The most common disease-causing mutation (DOK7(1124_1127 dup)) truncates DOK7 and leads to the loss of two tyrosine residues that are phosphorylated and recruit CRK proteins, which are important for anchoring acetylcholine receptors at synapses. Here we describe a mouse model of this common form of CM (Dok7(CM) mice) and a mouse with point mutations in the two tyrosine residues (Dok7(2YF)). We show that Dok7(CM) mice had severe deficits in neuromuscular synapse formation that caused neonatal lethality. Unexpectedly, these deficits were due to a severe deficiency in phosphorylation and activation of muscle-specific kinase (MUSK) rather than a deficiency in DOK7 tyrosine phosphorylation. We developed agonist antibodies against MUSK and show that these antibodies restored neuromuscular synapse formation and prevented neonatal lethality and late-onset disease in Dok7(CM) mice. These findings identify an unexpected cause for disease and a potential therapy for both DOK7 CM and other forms of CM caused by mutations in AGRIN, LRP4 or MUSK, and illustrate the potential of targeted therapy to rescue congenital lethality. |
